bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY
Benzinga Newsdesk 5 months ago
News
bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:Expansion of ordering physician sitesIncreased
bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:
- Expansion of ordering physician sites
- Increased peer-to-peer education among pulmonologists
- Integration of CyPath® Lung into clinical workflows for lung cancer risk assessment and nodule management